The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes

Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Journal of diabetes and its complications (Impact Factor: 3.01). 11/2010; 25(4):211-5. DOI: 10.1016/j.jdiacomp.2010.09.005
Source: PubMed


To determine whether continuous subcutaneous insulin infusion (CSII) or multiple daily injections of insulin (MDI) are associated with improved glycemic variability.
Type 2 diabetic patients ≥60 years of age were randomized to 12 months of CSII (n=53) or MDI (n=54) therapy. Patients were asked to complete monthly eight-point self-monitored glucose profiles (n=78) and continuous glucose monitoring systems (CGMS) for up to 72 h at Months 0, 6, and 12 (n=77). Within-day mean glucose, standard deviation (SD), range, pre- and post-prandial glucose, M value, and mean amplitude of glycemic excursions (MAGE) were calculated from eight-point profiles. Mean glucose, SD, range, area under the curve (AUC) high (>180 mg/dl) and AUC-low (<70 mg/dl) were calculated from CGMS. Mixed model analyses of variance were used to examine the associations between treatment, time, and the study outcomes, adjusting for any effects of sex.
With the use of the eight-point profiles, CSII and MDI groups did not differ with respect to mean glucose, mean pre-prandial and post-prandial glucose, SD, range, M value, or MAGE. With the CGMS data, there were no significant between-group differences in measures of mean glucose, range, SD, AUC-high, or AUC-low. In both treatment groups, all measures improved over time (P<.0001) except for AUC-low (P=.68) which did not change. There were treatment-by-time interactions when considering the CGMS range (P=.04) and AUC-high (P=.001), but no significant differences were found at individual time points.
Glucose variability improved equally with CSII and MDI treatment in older patients with type 2 diabetes.

1 Follower
7 Reads

  • Hospital pharmacy 10/2010; 45(10):803-804, C3. DOI:10.1310/hpj4510-803
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the effectiveness of insulin pump use (CSII) in patients with type 2 diabetes (DM2) who have failed multiple daily injection therapy (MDI)Methods: In this retrospective study, charts of patients with DM2 who were started on CSII after failure of MDI were reviewed. Patients were categorized as primarily manual (fixed) bolus users or calculated (using pump software) bolus users. The change in HbA1c, weight, and basal insulin dose from baseline to 6 months was determined.Results: Fifty-seven patients (20 men and 37 women) ranging in age from 13 to 71 were identified in the study. A significant reduction in HbA1c was observed from 8.75% to 7.69% (p < 0.001). There was an increase in BMI, from a mean of 36.53 to a mean of 37.21. A decrease in basal insulin requirement per kilogram of weight (- 0.10 U/kg) was noted (P=0.03). Seven patients using U-500 insulin in the pump also had a significant decrease in HbA1C of 1.1 % (p < 0.001), along with a 0.071 U/Kg drop in basal insulin requirements (p < 0.001). When comparing calculated bolus users to manual bolus users, there was no difference in HbA1C improvement (P= 0.58).Conclusions: We found that CSII in patients with DM2 who have failed MDI improves glucose control despite a decrease in overall insulin requirements. This includes patients with severe insulin resistance using U-500 insulin. Use of frequent bolus adjustment incorporating carbohydrate counting and current glucose level does not appear to be required for this benefit.
    Endocrine Practice 09/2012; 19(1):1-17. DOI:10.4158/EP12104.OR · 2.81 Impact Factor

  • Canadian Journal of Diabetes 04/2013; 37(suppl 1):S184–S190. DOI:10.1016/j.jcjd.2013.01.045 · 2.00 Impact Factor
Show more